Onyx in-licenses BTG's BGC 945

BTG (LSE:BGC) granted Onyx (NASDAQ:ONXX) exclusive, worldwide rights to preclinical cancer compound BGC 945. The molecule, which Onyx named ONX 0801, inhibits thymidylate synthase (TS) on cancer cells. BTG will receive $13 million up front and is eligible for up to $72 million in development and regulatory milestones, plus additional regulatory and commercialization milestones and royalties. ...